Product

AZD6094

Aliases

Part C - AZD6094 monotherapy (Japan only), savolitinib, Savolitinib/Volitinib

Name

savolitinib

1 clinical trial

1 indication

Indication

Clinical trial

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).

Status: Active (not recruiting), Estimated PCD: 2020-03-04